The Cost of Hyperkalemia in the United States
There are limited data on the cost of hyperkalemia. Methods: This retrospective analysis of the Truven MarketScan claims database assessed the economic burden of hyperkalemia among selected adult patients with hyperkalemia and matched controls. Results: A total of 39,626 cases (patients with hyperka...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2018-03-01
|
| Series: | Kidney International Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024917304382 |
| _version_ | 1818963143798292480 |
|---|---|
| author | Keith A. Betts J. Michael Woolley Fan Mu Cheryl Xiang Wenxi Tang Eric Q. Wu |
| author_facet | Keith A. Betts J. Michael Woolley Fan Mu Cheryl Xiang Wenxi Tang Eric Q. Wu |
| author_sort | Keith A. Betts |
| collection | DOAJ |
| description | There are limited data on the cost of hyperkalemia.
Methods: This retrospective analysis of the Truven MarketScan claims database assessed the economic burden of hyperkalemia among selected adult patients with hyperkalemia and matched controls.
Results: A total of 39,626 cases (patients with hyperkalemia) were matched to 39,626 controls (patients without hyperkalemia) based on age, dialysis, chronic kidney disease (CKD) stage, heart failure, and renin-angiotensin aldosterone system inhibitor use. Compared with controls, cases incurred $4128 (95% confidence interval [CI] $3893–$4363) higher 30-day total health care costs ($5994 vs. $1865) and $15,983 (95% CI $15,026–$16,940) higher 1-year costs ($31,844 vs. $15,861). Among 11,221 matched pairs of patients with CKD and/or heart failure, cases incurred $5553 (95% CI $5059–$6047) higher 30-day total health care costs ($8165 vs. $2612) and $24,133 (95% CI $21,748–$26,518) higher 1-year costs ($48,994 vs. $24,861) than controls. The multivariable adjusted 1-year total health care cost difference was $15,606 (95% CI $14,648–$16,576) among all patients and $25,156 (95% CI $23,529–$26,757) among patients with CKD and/or heart failure. Cases had higher resource utilization rates including inpatient admissions (30-day: 0.14 vs. 0.03; 1-year: 0.44 vs. 0.19), outpatient visits (30-day: 3.33 vs. 2.28; 1-year: 26.58 vs. 18.53), and emergency department visits (30-day: 0.16 vs. 0.06; 1-year: 0.86 vs. 0.50) (all P < 0.001). When hospitalized, cases stayed 1.51 days (95% CI 1.22–1.80) longer and were 40% more likely to be readmitted.
Conclusion: These data indicate that hyperkalemia is associated with a significant economic burden on afflicted patients and the health care system. |
| first_indexed | 2024-12-20T12:40:32Z |
| format | Article |
| id | doaj.art-6d625d0e5fb044d2a50315afcf5f9a95 |
| institution | Directory Open Access Journal |
| issn | 2468-0249 |
| language | English |
| last_indexed | 2024-12-20T12:40:32Z |
| publishDate | 2018-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Kidney International Reports |
| spelling | doaj.art-6d625d0e5fb044d2a50315afcf5f9a952022-12-21T19:40:30ZengElsevierKidney International Reports2468-02492018-03-013238539310.1016/j.ekir.2017.11.003The Cost of Hyperkalemia in the United StatesKeith A. Betts0J. Michael Woolley1Fan Mu2Cheryl Xiang3Wenxi Tang4Eric Q. Wu5Analysis Group, Inc., Boston, Massachusetts, USAZS Pharma, a member of the AstraZeneca Group, San Mateo, California, USAAnalysis Group, Inc., Boston, Massachusetts, USAAnalysis Group, Inc., Boston, Massachusetts, USAAnalysis Group, Inc., Boston, Massachusetts, USAAnalysis Group, Inc., Boston, Massachusetts, USAThere are limited data on the cost of hyperkalemia. Methods: This retrospective analysis of the Truven MarketScan claims database assessed the economic burden of hyperkalemia among selected adult patients with hyperkalemia and matched controls. Results: A total of 39,626 cases (patients with hyperkalemia) were matched to 39,626 controls (patients without hyperkalemia) based on age, dialysis, chronic kidney disease (CKD) stage, heart failure, and renin-angiotensin aldosterone system inhibitor use. Compared with controls, cases incurred $4128 (95% confidence interval [CI] $3893–$4363) higher 30-day total health care costs ($5994 vs. $1865) and $15,983 (95% CI $15,026–$16,940) higher 1-year costs ($31,844 vs. $15,861). Among 11,221 matched pairs of patients with CKD and/or heart failure, cases incurred $5553 (95% CI $5059–$6047) higher 30-day total health care costs ($8165 vs. $2612) and $24,133 (95% CI $21,748–$26,518) higher 1-year costs ($48,994 vs. $24,861) than controls. The multivariable adjusted 1-year total health care cost difference was $15,606 (95% CI $14,648–$16,576) among all patients and $25,156 (95% CI $23,529–$26,757) among patients with CKD and/or heart failure. Cases had higher resource utilization rates including inpatient admissions (30-day: 0.14 vs. 0.03; 1-year: 0.44 vs. 0.19), outpatient visits (30-day: 3.33 vs. 2.28; 1-year: 26.58 vs. 18.53), and emergency department visits (30-day: 0.16 vs. 0.06; 1-year: 0.86 vs. 0.50) (all P < 0.001). When hospitalized, cases stayed 1.51 days (95% CI 1.22–1.80) longer and were 40% more likely to be readmitted. Conclusion: These data indicate that hyperkalemia is associated with a significant economic burden on afflicted patients and the health care system.http://www.sciencedirect.com/science/article/pii/S2468024917304382costshealth care resource utilizationhospital readmissionhyperkalemia |
| spellingShingle | Keith A. Betts J. Michael Woolley Fan Mu Cheryl Xiang Wenxi Tang Eric Q. Wu The Cost of Hyperkalemia in the United States Kidney International Reports costs health care resource utilization hospital readmission hyperkalemia |
| title | The Cost of Hyperkalemia in the United States |
| title_full | The Cost of Hyperkalemia in the United States |
| title_fullStr | The Cost of Hyperkalemia in the United States |
| title_full_unstemmed | The Cost of Hyperkalemia in the United States |
| title_short | The Cost of Hyperkalemia in the United States |
| title_sort | cost of hyperkalemia in the united states |
| topic | costs health care resource utilization hospital readmission hyperkalemia |
| url | http://www.sciencedirect.com/science/article/pii/S2468024917304382 |
| work_keys_str_mv | AT keithabetts thecostofhyperkalemiaintheunitedstates AT jmichaelwoolley thecostofhyperkalemiaintheunitedstates AT fanmu thecostofhyperkalemiaintheunitedstates AT cherylxiang thecostofhyperkalemiaintheunitedstates AT wenxitang thecostofhyperkalemiaintheunitedstates AT ericqwu thecostofhyperkalemiaintheunitedstates AT keithabetts costofhyperkalemiaintheunitedstates AT jmichaelwoolley costofhyperkalemiaintheunitedstates AT fanmu costofhyperkalemiaintheunitedstates AT cherylxiang costofhyperkalemiaintheunitedstates AT wenxitang costofhyperkalemiaintheunitedstates AT ericqwu costofhyperkalemiaintheunitedstates |